AbbVie (ABBV) Projected to Announce Earnings on Friday

AbbVie (NYSE:ABBV) will likely be announcing its Q2 2026 results before the market opens on Friday, July 31st. Analysts expect the company to post earnings of $3.60 per share and revenue of $16.7870 billion for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, July 31, 2026 at 9:00 AM ET.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.46 EPS. On average, analysts expect AbbVie to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

AbbVie Stock Up 1.4%

ABBV opened at $256.80 on Friday. The firm has a market cap of $453.71 billion, a PE ratio of 126.50, a P/E/G ratio of 0.84 and a beta of 0.30. The business has a fifty day simple moving average of $233.60 and a 200-day simple moving average of $222.61. AbbVie has a fifty-two week low of $187.62 and a fifty-two week high of $261.64.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.7%. AbbVie’s payout ratio is 340.89%.

Hedge Funds Weigh In On AbbVie

Several institutional investors and hedge funds have recently bought and sold shares of the business. T. Rowe Price Investment Management Inc. increased its holdings in shares of AbbVie by 38.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 25,847 shares of the company’s stock valued at $5,906,000 after purchasing an additional 7,116 shares during the period. Strive Financial Group LLC acquired a new stake in shares of AbbVie during the fourth quarter worth approximately $216,000. Blue Sparrow LLC DE acquired a new stake in shares of AbbVie during the fourth quarter worth approximately $28,561,000. Mercer Global Advisors Inc. ADV grew its position in AbbVie by 5.9% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 430,631 shares of the company’s stock valued at $100,411,000 after purchasing an additional 23,859 shares in the last quarter. Finally, Summit Global Investments grew its position in AbbVie by 21.4% during the fourth quarter. Summit Global Investments now owns 16,916 shares of the company’s stock valued at $3,865,000 after purchasing an additional 2,987 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Canaccord Genuity raised its price target on AbbVie to $282 from $273 and reiterated a buy rating, signaling continued confidence in the company’s earnings power and pipeline. Benzinga / The Fly report
• Positive Sentiment: AbbVie’s Allergan Aesthetics unit won European Commission approval for Boey, a short-acting botulinum toxin, expanding its aesthetics portfolio and adding another growth driver outside its core immunology business. Yahoo Finance article
• Neutral Sentiment: Several commentary pieces highlighted AbbVie as a high-quality dividend stock and suggested its long-term outlook remains attractive, but that much of the optimism may already be reflected in the share price. Motley Fool article
• Negative Sentiment: Genmab and AbbVie clarified that the U.S. primary endpoint in the Phase 3 EPCORE DLBCL-1 trial was overall survival, and that endpoint was not met, which could pressure sentiment around AbbVie’s oncology franchise and the epcoritamab program. Yahoo Finance article
• Negative Sentiment: Analyst coverage also noted AbbVie’s oncology revenue may remain under pressure in Q2, as weakness in Imbruvica could offset gains from Venclexta and newer therapies. Yahoo Finance article

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Cantor Fitzgerald upped their target price on AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a report on Monday, July 6th. HSBC reissued a “buy” rating and issued a $300.00 price target on shares of AbbVie in a research note on Monday, July 6th. Citigroup upped their price objective on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. UBS Group upped their price objective on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a research note on Monday, July 13th. Finally, Guggenheim raised their target price on shares of AbbVie from $249.00 to $261.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $268.10.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.